<DOC>
	<DOCNO>NCT00660959</DOCNO>
	<brief_summary>The present study design confirm extend observation previous study lixivaptan therapy corrects hyponatremia , euvolemic subject , include subject SIADH .</brief_summary>
	<brief_title>Multicenter , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Oral Lixivaptan Capsules Subject With Euvolemic Hyponatremia</brief_title>
	<detailed_description>Phase I Phase II clinical trial demonstrate lixivaptan may play important role treat hyponatremia sign symptom water retention associate HF , liver cirrhosis ascites ( LCWA ) syndrome inappropriate antidiuretic hormone ( SIADH ) . Lixivaptan previously evaluate disease state characterize hyponatremia euvolemia ( SIADH ) hyponatremia combine fluid overload ( HF , LCWA ) . Lixivaptan result correction hyponatremia together mark aquaresis subject volume overload . The present study design confirm extend observation previous study lixivaptan therapy corrects hyponatremia , euvolemic subject , include subject SIDH .</detailed_description>
	<mesh_term>Hyponatremia</mesh_term>
	<criteria>Written inform consent Men woman age 18 old Diagnosis euvolemic hyponatremia ( 120 ≤ Na+ &lt; 130 mEq/L ) Hospitalized willing admit monitor set approximately first 48 hour treatment Pregnant breastfeeding woman , woman plan become pregnant breastfeed Symptomatic hyponatremia ( e.g. , lethargy , coma , seizures , change mental status attributable hyponatremia ) Acute transient hyponatremia ( e.g. , associate head trauma postoperative state ) Hyponatremia hypovolemic state . Hypovolemic hyponatremia define presence clinical evidence extracellular fluid volume depletion Hyponatremia result medication safely withdrawn Hyponatremia due hypothyroidism adrenal insufficiency Diagnosis psychogenic polydipsia Receiving within 7 day enrollment , medication treatment hyponatremia specifically : demeclocycline , lithium carbonate , urea , conivaptan Use radiotherapy chemotherapy within 2 wks randomization Likely require , receive IV saline correction symptomatic asymptomatic severe hyponatremia course study Supine systolic arterial blood pressure ≤ 90 mmHg Serum creatinine &gt; 3.0 mg/dL History uncontrolled type 2 diabetes mellitus Severe pulmonary artery hypertension : patient whose condition expect deteriorate sudden shift fluid volume cardiac filling pressure Established diagnosis New York Heart Association ( NYHA ) class III IV heart failure History myocardial infarction , unstable angina evidence active ischemia within 30 day prior screen History cerebral vascular accident ( CVA ) within 60 day prior screen Established diagnosis nephrotic syndrome Advanced liver disease document diagnosis cirrhosis alcoholic hepatitis Urinary tract obstruction ( benign prostatic hypertrophy [ BPH ] allow nonobstructive ) History alcohol abuse illicit drug use within past 6 month Terminally ill moribund condition little chance shortterm survival Receiving vasopressin analog treatment condition Known allergy vasopressin antagonist Previous participation lixivaptan study Recipient investigational treatment ( drug device ) within 30 day prior baseline visit Unable take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Euvolemic</keyword>
	<keyword>Hyponatremia</keyword>
	<keyword>Serum Sodium</keyword>
	<keyword>Fluid Overload</keyword>
	<keyword>Vasopressin Antagonist</keyword>
</DOC>